is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Sorafenib is a small molecular inhibitor of several Tyrosine protein kinases. (Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous). Sorafenib works along the multiple signaling pathways to block cell proliferation and tumor angiogenesis. It blocks the receptor tyrosine kinases VEGFR (Vascular Endothelial Growth Factor Receptor) and PDGFR (Platelet Derived Growth Factor Receptor) and the RAF serine/threonine kinases along the RAF/MEK/ERK pathway.
SEND INQUIRY
Please fill in fully your information to send email